In other findings, technical success was 98% with the Chocolate Touch DCB and 86% with the Lutonix DCB, and device success was 99.4% and 85.3%, respectively. Clinical improvement was similar, at ...

According to an interim analysis from a registry presented at VIVA 17, a drug-coated balloon was safe and effective at 12 months. Edward Y. Woo, MD , FACS , presented an interim analysis of 627 ...

LAS VEGAS, Sept. 12, 2017 /PRNewswire-USNewswire/ -- VIVA Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and ...

Surmodics Avess™ AV Fistula DCB First-in-Human Study ... thrombosis and loss,” said Ramon L. Varcoe, MD, MBBS, MS, FRFRACS, PhD, associate professor of vascular surgery at Prince of ...

European Journal of Vascular and Endovascular Surgery Publishes Results Showing Comparable Safety and Efficacy of SurVeil™ DCB Despite IN.PACT™ Admiral™ DCB having 75% Higher Paclitaxel Dose.

LAS VEGAS, Sept. 13, 2017 /PRNewswire-USNewswire/ -- VIVA Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and ...

European Journal of Vascular and Endovascular Surgery Publishes Results Showing Comparable Safety and Efficacy of SurVeil™ DCB Despite IN.PACT™ Admiral™ DCB having 75% Higher Paclitaxel Dose ...

The drug-coated balloon (DCB) for peripheral interventions had its share of troubles in recent years before making a comeback, with the field of available devices perhaps even poised for expansion ...